Nwam LLC Raises Holdings in Novo Nordisk A/S $NVO

Nwam LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 331.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,662 shares of the company’s stock after acquiring an additional 15,872 shares during the quarter. Nwam LLC’s holdings in Novo Nordisk A/S were worth $759,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. CIBC Bancorp USA Inc. purchased a new position in shares of Novo Nordisk A/S during the third quarter worth $19,519,000. Romano Brothers AND Company boosted its holdings in Novo Nordisk A/S by 704.0% during the 4th quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock valued at $1,742,000 after acquiring an additional 29,978 shares during the period. Capital Investment Counsel LLC purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $3,727,000. Marathon Capital Management grew its position in Novo Nordisk A/S by 43.9% in the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock valued at $4,208,000 after acquiring an additional 25,230 shares in the last quarter. Finally, CWA Asset Management Group LLC lifted its position in shares of Novo Nordisk A/S by 131.9% during the fourth quarter. CWA Asset Management Group LLC now owns 76,993 shares of the company’s stock worth $3,917,000 after purchasing an additional 43,793 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $51.50 on Friday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a market capitalization of $229.96 billion, a PE ratio of 12.09, a price-to-earnings-growth ratio of 4.61 and a beta of 0.77. The business’s fifty day moving average price is $46.01 and its 200 day moving average price is $45.79.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion during the quarter. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The European Commission approved Novo Nordisk’s once-daily oral Wegovy pill for obesity, making it the first GLP-1 tablet cleared for weight management in the EU and expanding the company’s addressable market. Reuters article on EU approval
• Positive Sentiment: Multiple reports said the oral Wegovy approval could help Novo Nordisk extend its lead over Eli Lilly in obesity treatment, reinforcing optimism around the company’s long-term growth in diabetes and weight-loss therapies. Pharmaceutical Technology article on competition with Lilly
• Positive Sentiment: Analysts and market commentary pointed to improved growth expectations and higher fair value estimates after the approval, signaling that sentiment around Novo’s obesity pipeline has improved. Yahoo Finance article on fair value estimate
• Neutral Sentiment: Novo also announced a new Phase 3 heart failure–obesity trial, which supports its cardiometabolic strategy but is still early-stage and unlikely to affect near-term results. TipRanks article on trial update
• Negative Sentiment: Separate news that Sun Pharma won approval in South Africa for a generic version of semaglutide highlights ongoing competitive and copycat-drug pressure on Novo Nordisk’s key products. Reuters article on generic Ozempic approval
• Negative Sentiment: Zacks Research downgraded Novo Nordisk from hold to strong sell, showing that not all analysts are convinced the stock’s recent strength will continue. Tickerreport article on downgrade

Analyst Upgrades and Downgrades

NVO has been the topic of several recent research reports. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Finally, HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Five analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.